ABBV vs VRTV: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Veritiv Corporation — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-07-06.
AbbVie Inc. · Healthcare
$261.07
+1.2% upside to fair value
Grade C
High Quality
VS
Veritiv Corporation · Industrials
$169.99
-43.3% upside to fair value
Grade D
QuantHub Verdict
ABBV has more upside to fair value
(+1.2%).
VRTV trades at a lower forward P/E
(7.1x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
VRTV |
| Current Price |
$261.07 |
$169.99 |
| Fair Value Estimate |
$264.30 |
$96.38 |
| Upside to Fair Value |
+1.2%
|
-43.3%
|
| Market Cap |
$461.3B |
$2.3B |
| Forward P/E |
128.0x
|
7.1x
|
| EV / EBITDA |
31.0x
|
5.4x
|
| Price / Sales |
7.3x
|
0.3x
|
| Price / FCF |
22.1x
|
10.0x
|
| Revenue Growth YoY |
+12.4%
|
-19.0%
|
| Gross Margin |
70.7%
|
22.7%
|
| Operating Margin |
27.6%
|
5.9%
|
| Return on Equity |
68.0%
|
48.6%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
4.52%
|
9.99%
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
AbbVie Inc. is a leading healthcare company specializing in drug manufacturing with a strong focus on immunology and aesthetics. The company is transitioning from its historical Humira dominance, which has faced loss of exclusivity, toward high-growth assets like Skyrizi and Rinvoq that are driving robust revenue growth of 12.4% in the most recent quarter. Despite strong revenue growth and a dura…
Veritiv Corporation operates as a distributor primarily in packaging, facility solutions, and print markets, with a business quality characterized by scale and network density rather than proprietary products or pricing power. The company has undergone significant transformation under CEO Salvatore A. Abbate, including a take-private transaction by Clayton, Dubilier & Rice in 2023 and a strategic…
Accumulation Zones
| Metric |
ABBV |
VRTV |
| Zone Low |
$198.23 |
$72.28 |
| Zone High |
$224.66 |
$81.92 |
| In Buy Zone? |
No
|
No
|